Hidradenitis Suppurativa: Clinical Outcomes for Bimekizumab Positive in Phase 3 Studies

<?xml version="1.0" encoding="UTF-8"?>
<!--$RCSfile: InCopy_agile.xsl,v $ $Revision: 1.35 $-->
<!--$RCSfile: drupal.xsl,v $ $Revision: 1.7 $-->
<root generator="drupal.xsl" gversion="1.7"> <header> <fileName>168368</fileName> <TBEID>0C0507F9.SIG</TBEID> <TBUniqueIdentifier>MD_0C0507F9</TBUniqueIdentifier> <newsOrJournal>News</newsOrJournal> <publisherName>Frontline Medical Communications</publisherName> <storyname/> <articleType>2</articleType> <TBLocation>QC Done-All Pubs</TBLocation> <QCDate>20240612T100105</QCDate> <firstPublished>20240612T103113</firstPublished> <LastPublished>20240612T103113</LastPublished> <pubStatus qcode="stat:"/> <embargoDate/> <killDate/> <CMSDate>20240612T103113</CMSDate> <articleSource/> <facebookInfo/> <meetingNumber/> <byline>Shrabasti Bhattacharya</byline> <bylineText>SHRABASTI BHATTACHARYA</bylineText> <bylineFull>SHRABASTI BHATTACHARYA</bylineFull> <bylineTitleText/> <USOrGlobal/> <wireDocType/> <newsDocType>News</newsDocType> <journalDocType/> <linkLabel/> <pageRange/> <citation/> <quizID/> <indexIssueDate/> <itemClass qcode="ninat:text"/> <provider qcode="provider:imng"> <name>IMNG Medical Media</name> <rightsInfo> <copyrightHolder> <name>Frontline Medical News</name> </copyrightHolder> <copyrightNotice>Copyright (c) 2015 Frontline Medical News, a Frontline Medical Communications Inc. company. All rights reserved. This material may not be published, broadcast, copied, or otherwise reproduced or distributed without the prior written permission of Frontline Medical Communications Inc.</copyrightNotice> </rightsInfo> </provider> <abstract/> <metaDescription>Bimekizumab, currently approved for treating psoriasis, was well tolerated and reduced abscesses and the number of inflammatory nodules in patients with moderat</metaDescription> <articlePDF/> <teaserImage/> <teaser>The primary outcome was an HS clinical response of at least 50% at week 16, defined as at least a 50% reduction in total abscess and inflammatory nodule count.</teaser> <title>Hidradenitis Suppurativa: Clinical Outcomes for Bimekizumab Positive in Phase 3 Studies</title> <deck/> <disclaimer/> <AuthorList/> <articleURL/> <doi/> <pubMedID/> <publishXMLStatus/> <publishXMLVersion>1</publishXMLVersion> <useEISSN>0</useEISSN> <urgency/> <pubPubdateYear/> <pubPubdateMonth/> <pubPubdateDay/> <pubVolume/> <pubNumber/> <wireChannels/> <primaryCMSID/> <CMSIDs/> <keywords/> <seeAlsos/> <publications_g> <publicationData> <publicationCode>skin</publicationCode> <pubIssueName/> <pubArticleType/> <pubTopics/> <pubCategories/> <pubSections/> </publicationData> <publicationData> <publicationCode>fp</publicationCode> <pubIssueName/> <pubArticleType/> <pubTopics/> <pubCategories/> <pubSections/> </publicationData> <publicationData> <publicationCode>im</publicationCode> <pubIssueName/> <pubArticleType/> <pubTopics/> <pubCategories/> <pubSections/> </publicationData> </publications_g> <publications> <term canonical="true">13</term> <term>15</term> <term>21</term> </publications> <sections> <term canonical="true">39313</term> <term>27970</term> </sections> <topics> <term canonical="true">39212</term> <term>203</term> </topics> <links/> </header> <itemSet> <newsItem> <itemMeta> <itemRole>Main</itemRole> <itemClass>text</itemClass> <title>Hidradenitis Suppurativa: Clinical Outcomes for Bimekizumab Positive in Phase 3 Studies</title> <deck/> </itemMeta> <itemContent> <h2>TOPLINE:</h2> <p><span class="tag metaDescription">Bimekizumab, currently approved for treating psoriasis, was well tolerated and reduced abscesses and the number of inflammatory nodules in patients with moderate to severe hidradenitis suppurativa (HS)</span>, in two phase 3 studies.</p> <h2>METHODOLOGY:</h2> <ul class="body"> <li>To assess the efficacy and safety of bimekizumab, an interleukin (IL)-17A and IL-17F antagonist, 320 mg for HS, researchers conducted two 48-week phase 3 trials <a href="https://www.clinicaltrials.gov/study/NCT04242446?term=BE%20HEARD%20I&amp;rank=1">BE HEARD I</a> (n = 505) and <a href="https://www.clinicaltrials.gov/study/NCT04242498?term=BE%20HEARD%20II&amp;rank=1">II</a> (n = 509), which enrolled patients with moderate to severe HS and a history of inadequate response to systemic antibiotics.</li> <li>Patients were randomly assigned to one of four groups: Bimekizumab every 2 weeks, bimekizumab every 2 weeks for 16 weeks followed by every 4 weeks of dosing, bimekizumab every 4 weeks, or placebo for 16 weeks followed by bimekizumab every 2 weeks.</li> <li>The primary outcome was an HS clinical response of at least 50% (HiSCR50) at week 16, defined as at least a 50% reduction in total abscess and inflammatory nodule count.</li> </ul> <h2>TAKEAWAY:</h2> <ul class="body"> <li>A higher proportion of patients receiving bimekizumab every 2 weeks vs placebo achieved an HiSCR50 response at week 16 in BE HEARD I (48% vs 29%; odds ratio [OR], 2.23; <em>P</em> = .006) and II (52% vs 32%; OR, 2.29; <em>P</em> = .0032) trials.</li> <li>Patients receiving bimekizumab every 4 weeks also achieved a higher HiSCR50 response at week 16 vs placebo in the BE HEARD II trial (54% vs 32%; OR, 2.42; <em>P</em> = .0038).</li> <li>At week 16, a higher proportion of patients receiving bimekizumab every 2 weeks vs placebo achieved at least a 75% HiSCR (HiSCR75) in both trials, and a higher proportion of those receiving bimekizumab every 4 weeks achieved HiSCR75 in the BE HEARD II trial.</li> <li>At week 48, 45%-68% of patients achieved HiSCR50 in both trials.</li> <li>Patients who received bimekizumab vs placebo for the initial 16 weeks had greater improvements in patient-reported outcomes, and bimekizumab was well tolerated with a low number of serious or severe treatment-emergent adverse events.</li> </ul> <h2>IN PRACTICE:</h2> <p>“Bimekizumab was well tolerated by patients with hidradenitis suppurativa and produced rapid and deep clinically meaningful responses that were maintained up to 48 weeks,” the authors wrote. “These data support the use of bimekizumab as a promising new therapeutic option for patients with moderate to severe hidradenitis suppurativa.”</p> <h2>SOURCE:</h2> <p>Alexa B. Kimball, MD, MPH, from Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, led this study, which was published <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00101-6/abstract">online</a> in <em>The Lancet</em>. </p> <h2>LIMITATIONS:</h2> <p>The placebo-controlled part of this trial was relatively short at 16 weeks and may affect the interpretation of later efficacy data, there was a lack of an active comparator group, and the efficacy of treatment was evaluated in the presence of rescue treatment with systemic antibiotics.</p> <h2>DISCLOSURES:</h2> <p>The studies were funded by bimekizumab manufacturer UCB Pharma. Seven authors disclosed being current or former employees of UCB Pharma. Other authors reported several ties with many companies, including UCB Pharma.<span class="end"/></p> <p> <em>A version of this article first appeared on <span class="Hyperlink"><a href="https://www.medscape.com/viewarticle/phase-3-trials-bimekizumab-effective-moderate-severe-2024a1000alz">Medscape.com</a></span>.</em> </p> </itemContent> </newsItem> <newsItem> <itemMeta> <itemRole>teaser</itemRole> <itemClass>text</itemClass> <title/> <deck/> </itemMeta> <itemContent> </itemContent> </newsItem> </itemSet></root>